Showing results (81-90 of 546) with videos related to
Sort By:
Pageof 55
Archives Des Maladies Du Coeur Et Des Vaisseaux|May 1, 1988
[Hemorrhagic risk in intravenously administered thrombolytic treatment in acute myocardial infarction]J Acar, R Dorent, A Vahanian, et al.Thrombosis Research|November 5, 2002
Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutationI Gouin-Thibault, R Arkam, S Nassiri, et al.Thrombosis Research. Supplement|January 1, 1991
Anti Xa activity and prothrombinase inhibition in patients treated with two different doses of enoxaparin in gynecologic surgeryM M Samama, S Combe, M H Horellou, et al.Archives Des Maladies Du Coeur Et Des Vaisseaux|February 1, 1990
[Anistreplase. Pharmacology and biological data]M SamamaAnnales De Biologie Clinique|January 1, 1984
[Diagnosis of defibrination syndromes in infectious pathology]M SamamaArchives Des Maladies Du Coeur Et Des Vaisseaux|October 1, 1986
[Tissue plasminogen activator (t-PA) in myocardial infarction. Biological aspects]M Samama, E Verdy, J Conard, et al.Blood|August 15, 1993
Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiencyJ Conard, K A Bauer, A Gruber, et al.Fundamental & Clinical Pharmacology|January 1, 1988
Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitroM Samama, G Nguyen, P Desnoyers, et al.Annales De Medecine Interne|January 1, 1983
[4 cases of acquired Willebrand factor deficiency associated with monoclonal dysglobulinemia]M H Horellou, E Baumelou, N Sitbon, et al.Pageof 55